PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.12 per share for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2021-11-04
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $12.02, a 20.68% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $9.96, a 64.12% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $27.76, a 62.18% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $73.40, a 101.32% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $10.03, a 34.87% decline from fiscal 2019.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $15.40, a 73.96% decline from fiscal 2018.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $59.13, a 52.12% increase from fiscal 2017.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $38.87, a 8.20% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2021-09-30 | $11.12 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $11.71 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $12.02 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $10.03 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $10.03 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $9.96 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $9.96 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $15.40 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $27.76 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $27.76 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $27.76 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $59.13 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $73.40 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $73.40 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $73.40 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $38.87 10-K · filed 2020-02-28 | |||
| 2017-09-30 | $38.87 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $38.87 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $36.46 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $42.34 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $45.02 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $46.24 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $60.82 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $117.62 10-K · filed 2018-03-09 | |||
| 2015-09-30 | $153.65 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $200.95 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $218.13 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $159.62 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $124.78 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | $95.19 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $106.86 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $44.77 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $36.80 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $28.72 10-Q · filed 2013-08-06 | |||
| 2013-03-31 | $26.44 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $11.48 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |